Adicet Bio (ACET) Cash & Current Investments (2017 - 2026)

Adicet Bio's Cash & Current Investments history runs 10 years deep, the most recent figure standing at $137.6 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 8.54% year-over-year to $137.6 million; the TTM figure through Mar 2026 stood at $137.6 million (down 8.54% YoY), while the FY2025 annual figure was $158.5 million, down 10.08% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $137.6 million, down from $158.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $282.7 million in Q3 2022, with the low at $103.1 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $183.3 million (2023), against an average of $193.9 million.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments surged 47.06% in 2022, then slumped 48.98% in 2025.
• Adicet Bio's Cash & Current Investments stood at $257.7 million in 2022, then plunged by 38.01% to $159.7 million in 2023, then increased by 10.39% to $176.3 million in 2024, then decreased by 10.08% to $158.5 million in 2025, then fell by 13.21% to $137.6 million in 2026.
• Business Quant data shows ACET's Cash & Current Investments at $137.6 million in Q1 2026, $158.5 million in Q4 2025, and $103.1 million in Q3 2025.